FMC1-LUC7L2 readthrough protein (FMC1-LUC7L2)

FMC1-LUC7L2 readthrough protein is a fusion protein produced by naturally occurring readthrough transcription between the neighboring genes C7orf55 (also known as FMC1, encoding a mitochondrial ATP synthase assembly factor) and LUC7L2 (encoding a putative RNA-binding protein) on human chromosome 7[2][9][4]. The resulting product shares sequence with both FMC1 and LUC7L2[2]. Limited functional data is available; based on its constituent domains, it may be involved in mitochondrial ATP synthase assembly (through its FMC1 region) or RNA-processing/splicing (through its LUC7L2 region)[5][3], but there is no evidence that the fusion protein exists as a functional entity in normal physiology or that it serves as a canonical therapeutic target. It is not classified as a well-established receptor, enzyme, transporter, or signaling molecule, and no known drugs or targeted therapies exist for this fusion protein[2][5][8]. Its clinical and biological significance remains unclear, and the entry likely represents a rare or bioinformatically predicted fusion product with little established biomedical relevance as a target. **Key issues / correctness:** This entry is a readthrough/fusion product, not a standalone validated therapeutic target, receptor, or functionally characterized protein. It does not fit standard molecular target definitions (such as receptor, enzyme, transporter, channel, etc.) and has not been implicated as a drug target, biomarker, or in drug action pathways[2][5][9].

Other names

C7orf55-LUC7L2C7orf55FMC1FMC1-LUC7L2 readthroughATP synthase assembly factor FMC1, mitochondrialFormation of mitochondrial complex V assembly factor 1 homologProtein FMC1 homolog